Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments.
BNT162b2 vaccine
COVID-19
SARS-CoV-2
anti-neoplastic treatment
antibodies
cancer patients
chemotherapy
immunocompromised
immunogenicity
Journal
Diseases (Basel, Switzerland)
ISSN: 2079-9721
Titre abrégé: Diseases
Pays: Switzerland
ID NLM: 101636232
Informations de publication
Date de publication:
26 Sep 2023
26 Sep 2023
Historique:
received:
22
08
2023
revised:
20
09
2023
accepted:
25
09
2023
medline:
24
10
2023
pubmed:
24
10
2023
entrez:
24
10
2023
Statut:
epublish
Résumé
The BNT162b2 vaccine is globally used for preventing morbidity and mortality related to COVID-19. Cancer patients have had priority for receiving the vaccine due to their diminished immunity. This study reports the response rate of administering the third and fourth vaccine doses to cancer patients receiving active anti-neoplastic treatment. A total of 142 patients received two doses of the mRNA-based BNT162b2 COVID-19 vaccine, while 76 and 25 patients received three and four doses, respectively. The efficacy of the humoral response following two vaccine doses was diminished in cancer patients, especially in the group of patients receiving chemotherapy. In a multivariate analysis, patients who received three and four BNT162b2 vaccine doses were more likely to have antibody titers in the upper tertile compared to patients who received two doses of the vaccine (odds ratio (OR) 7.62 (95% CI 1.38-42.12),
Identifiants
pubmed: 37873772
pii: diseases11040128
doi: 10.3390/diseases11040128
pmc: PMC10594524
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cancer Discov. 2020 Jun;10(6):783-791
pubmed: 32345594
Vaccines (Basel). 2023 Mar 31;11(4):
pubmed: 37112688
Intern Med J. 2021 Feb;51(2):199-205
pubmed: 33631862
J Pharm Pract. 2022 Dec;35(6):947-951
pubmed: 33840294
Infect Chemother. 2020 Jun;52(2):154-164
pubmed: 32537961
Nat Cancer. 2022 May;3(5):547-551
pubmed: 35379984
Lancet Oncol. 2021 Jun;22(6):738-739
pubmed: 34087120
Nat Rev Clin Oncol. 2022 Jun;19(6):385-401
pubmed: 35277694
N Engl J Med. 2021 Oct 21;385(17):1627-1629
pubmed: 34525276
Vaccines (Basel). 2022 Jan 25;10(2):
pubmed: 35214642
Lancet Rheumatol. 2022 Jun;4(6):e379-e380
pubmed: 35527809
N Engl J Med. 2021 Dec 9;385(24):e85
pubmed: 34706170
Med. 2022 Dec 9;3(12):827-837.e3
pubmed: 36198311
Cancer Rep (Hoboken). 2022 Aug;5(8):e1645
pubmed: 35652556
Lancet Oncol. 2021 Dec;22(12):1681-1691
pubmed: 34767759
Leukemia. 2021 Dec;35(12):3534-3541
pubmed: 34326466
NAM Perspect. 2021 Nov 29;2021:
pubmed: 35118349
Crit Care Clin. 2021 Jan;37(1):69-84
pubmed: 33190776
Semin Respir Crit Care Med. 2021 Dec;42(6):839-858
pubmed: 34918325
Front Oncol. 2021 Nov 04;11:759108
pubmed: 34804957
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
N Engl J Med. 2021 Aug 12;385(7):661-662
pubmed: 34161700
Cancers (Basel). 2021 Aug 20;13(16):
pubmed: 34439346
JAMA. 2021 Jul 23;:
pubmed: 34297036
Nat Med. 2021 Nov;27(11):2002-2011
pubmed: 34594036
JAMA Oncol. 2021 Aug 1;7(8):1133-1140
pubmed: 34047765
Br J Cancer. 2021 Sep;125(7):939-947
pubmed: 34400804
Cancers (Basel). 2022 Nov 25;14(23):
pubmed: 36497296
N Engl J Med. 2021 Dec 9;385(24):e84
pubmed: 34614326
Cancers (Basel). 2022 Jun 04;14(11):
pubmed: 35681774
Front Immunol. 2022 Sep 29;13:1017863
pubmed: 36248803
JAMA. 2021 Oct 19;326(15):1533-1535
pubmed: 34459863
Int Immunopharmacol. 2021 Oct;99:108021
pubmed: 34352567
Int J Biol Sci. 2022 Jul 11;18(12):4768-4780
pubmed: 35874958
Vaccine. 2022 Sep 16;40(39):5726-5731
pubmed: 36041940
Oncologist. 2023 Apr 6;28(4):e225-e227
pubmed: 36856804
N Engl J Med. 2022 Jan 13;386(2):105-115
pubmed: 34942066
Lancet. 2021 May 15;397(10287):1783-1785
pubmed: 33964221
Nat Rev Immunol. 2021 Apr;21(4):245-256
pubmed: 33723416
Life (Basel). 2021 Oct 12;11(10):
pubmed: 34685448
BMJ. 2022 Mar 2;376:e068632
pubmed: 35236664
Crit Rev Clin Lab Sci. 2020 Sep;57(6):365-388
pubmed: 32645276
Nat Rev Cancer. 2021 Jun;21(6):345-359
pubmed: 33837297
Lancet Oncol. 2021 Jun;22(6):765-778
pubmed: 33930323
N Engl J Med. 2021 Oct 7;385(15):1393-1400
pubmed: 34525275
Front Immunol. 2022 May 25;13:899972
pubmed: 35693807
Lancet Oncol. 2022 Feb;23(2):193-195
pubmed: 34953523
Vaccines (Basel). 2022 Oct 29;10(11):
pubmed: 36366338
ESMO Open. 2022 Apr;7(2):100458
pubmed: 35427842
Front Immunol. 2021 Sep 28;12:740708
pubmed: 34650563
EClinicalMedicine. 2021 Nov;41:101158
pubmed: 34693234
Front Microbiol. 2022 Sep 23;13:1002748
pubmed: 36212856
Eur J Cancer. 2022 Nov;176:164-167
pubmed: 36223679
Front Immunol. 2022 Oct 06;13:1004045
pubmed: 36275672
Int J Physiol Pathophysiol Pharmacol. 2021 Jun 15;13(3):86-93
pubmed: 34336132
Commun Med (Lond). 2022 Jun 29;2:76
pubmed: 35784447
Cancers (Basel). 2023 Apr 12;15(8):
pubmed: 37190194
N Engl J Med. 2022 Apr 28;386(17):1603-1614
pubmed: 35417631
Blood Cancer J. 2022 Dec 23;12(12):173
pubmed: 36550105
Eur J Intern Med. 2023 Jan;107:7-16
pubmed: 36379820
J Clin Virol. 2022 Jan;146:105057
pubmed: 34923323
Cancers (Basel). 2020 Nov 05;12(11):
pubmed: 33167313